Enzyme News and Research

RSS

FN-EDA protein can reduce damage after heart attack

Scientists have identified a protein that plays a key role in debilitating changes that occur in the heart after a heart attack, according to research reported in Circulation Research: Journal of the American Heart Association.

25 Feb 2011

Research: Loss of CMAH's function may make humans more prone to obesity and diabetes

As if the recent prediction that half of all Americans will have diabetes or pre-diabetes by the year 2020 isn't alarming enough, a new genetic discovery published online in the FASEB Journal provides a disturbing explanation as to why: we took an evolutionary "wrong turn."

25 Feb 2011

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, today announced the successful completion of a Phase 1 exposure-escalation clinical study with its synthetic defensin-mimetic antibiotic, PMX-30063.

24 Feb 2011

Stereotaxis reports first-ever use of Niobe Magnetic Navigation System to treat hypertension

Stereotaxis, Inc. announced today the first-ever use of its Niobe® Magnetic Navigation System in a renal artery ablation procedure for the treatment of chronic hypertension that was not treatable with medication.

24 Feb 2011

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Cell Signaling Technology, Inc. of Danvers, MA announced today a joint commercialization partnership with Astellas Pharma, Inc. of Tokyo, Japan focused on the delivery of personalized cancer therapeutics and diagnostics.

From Cell Signaling Technology 24 Feb 2011

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.

23 Feb 2011

Antiepileptic drugs could make HIV drugs less effective

A Michigan State University researcher is looking to uncover the risks of treating seizures in HIV-positive patients, providing much-needed data on possible interactions between antiepileptic drugs and antiretroviral medicines that potentially could make HIV drugs less effective or the disease itself drug resistant.

23 Feb 2011

Mutated cancer pathway studies identify therapeutic targets for congenital heart disease

Cross-disciplinary teams of scientists studying genetic pathways that are mutated in many forms of cancer, but which also cause certain forms of congenital heart disease - including hypertrophic cardiomyopathy, a thickening of the heart muscle that is the leading cause of sudden death in children and young adults -, have introduced these mutations into mice and successfully treated HCM in the lab.

22 Feb 2011

New study: Rapamycin reverses cardiac muscle damage in LEOPARD syndrome mouse model

Congenital heart diseases affect approximately one in 100 patients, making them the most common type of birth defect and the number-one cause of pediatric deaths.

21 Feb 2011

Researchers receive $2 million NIH grant to identify biomarkers in children with hemangiomas

A nearly $2 million grant from the National Institutes of Health will help investigators at Nationwide Children's Hospital search for biomarkers that may be linked to the development and outcome of hemangiomas, the most common soft tissue tumor in children.

21 Feb 2011

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Protalix BioTherapeutics, Inc., announced today that new clinical data from the switchover trial of taliglucerase alfa in Gaucher disease patients and preclinical data on oral enzyme glucocerebrosidase (oral GCD) will be presented today at the 7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011 in Las Vegas, Nevada.

19 Feb 2011

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint.

19 Feb 2011

New tuberculosis vaccine provides better protection

Nele Festjens and Nico Callewaert of VIB and Ghent University have improved the efficacy of the vaccine for tuberculosis. The new vaccine affords - as already proven in mice - better protection against the disease. The development of a new tuberculosis vaccine is a priority in the fight against the disease which claims the lives of 1.7 million people each year. The current vaccine provides only partial protection.

19 Feb 2011

Medical expert speaks about effects of sugar on human body

With the many forms of sugar available, from table sugar, to high-fructose corn syrup to agave and honey, understanding the differences between sugars and their effects on the body is not all sweet.

18 Feb 2011

Scientists investigate natural chemical compound in sea sponges to create novel anti-cancer drugs

Scientists in London are turning to sea sponges to help them learn more about anti-cancer drugs. Using his £106,079 grant from the Association for International Cancer Research Dr Matthew Fuchter and his team are investigating a naturally-occurring chemical found in the sea sponge.

18 Feb 2011

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.

18 Feb 2011

U.S. FDA approves Corifact to prevent bleeding in people with Factor XIII deficiency

The U.S. Food and Drug Administration today approved Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Progenics Pharmaceuticals, Inc. today reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen.

17 Feb 2011

CLC bio releases several desktop software packages for analyzing biological sequence data

Today, CLC bio announced the release of several desktop software packages for analyzing biological sequence data including the popular products such as the CLC Main Workbench 6.0 and CLC DNA Workbench 6.0.

17 Feb 2011

Enzyme News and Research

FN-EDA protein can reduce damage after heart attack

Research: Loss of CMAH's function may make humans more prone to obesity and diabetes

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

Stereotaxis reports first-ever use of Niobe Magnetic Navigation System to treat hypertension

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

Antiepileptic drugs could make HIV drugs less effective

Mutated cancer pathway studies identify therapeutic targets for congenital heart disease

New study: Rapamycin reverses cardiac muscle damage in LEOPARD syndrome mouse model

Researchers receive $2 million NIH grant to identify biomarkers in children with hemangiomas

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

New tuberculosis vaccine provides better protection

Medical expert speaks about effects of sugar on human body

Scientists investigate natural chemical compound in sea sponges to create novel anti-cancer drugs

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

U.S. FDA approves Corifact to prevent bleeding in people with Factor XIII deficiency

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

CLC bio releases several desktop software packages for analyzing biological sequence data

Measuring Drug-Target Residence Times with Biochemical Assays eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo